MA49884A - Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer - Google Patents

Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer

Info

Publication number
MA49884A
MA49884A MA049884A MA49884A MA49884A MA 49884 A MA49884 A MA 49884A MA 049884 A MA049884 A MA 049884A MA 49884 A MA49884 A MA 49884A MA 49884 A MA49884 A MA 49884A
Authority
MA
Morocco
Prior art keywords
deuterates
quinolin
imidazo
cancer
treatment
Prior art date
Application number
MA049884A
Other languages
English (en)
French (fr)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA49884A publication Critical patent/MA49884A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049884A 2017-03-16 2018-03-15 Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer MA49884A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
MA49884A true MA49884A (fr) 2020-06-24

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049884A MA49884A (fr) 2017-03-16 2018-03-15 Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer

Country Status (25)

Country Link
US (2) US20200087300A1 (enExample)
EP (1) EP3596076A1 (enExample)
JP (1) JP2020514344A (enExample)
KR (1) KR20190129923A (enExample)
CN (1) CN110431139B (enExample)
AU (1) AU2018234985B2 (enExample)
BR (1) BR112019018723A2 (enExample)
CA (1) CA3055258A1 (enExample)
CL (1) CL2019002527A1 (enExample)
CO (1) CO2019010029A2 (enExample)
CR (1) CR20190429A (enExample)
DO (1) DOP2019000228A (enExample)
EA (1) EA038233B1 (enExample)
EC (1) ECSP19066134A (enExample)
IL (1) IL269272A (enExample)
JO (1) JOP20190209A1 (enExample)
MA (1) MA49884A (enExample)
MX (1) MX2019010898A (enExample)
NI (1) NI201900094A (enExample)
PE (1) PE20191486A1 (enExample)
PH (1) PH12019502086A1 (enExample)
SG (1) SG11201908065YA (enExample)
TW (1) TW201843151A (enExample)
UA (1) UA124554C2 (enExample)
WO (1) WO2018167203A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
NZ596487A (en) * 2009-06-04 2012-11-30 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
CN107889488B (zh) * 2015-04-02 2020-08-11 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
UA124554C2 (uk) 2021-10-05
EA038233B1 (ru) 2021-07-28
BR112019018723A2 (pt) 2020-04-07
NI201900094A (es) 2020-03-18
AU2018234985B2 (en) 2020-04-02
IL269272A (en) 2019-11-28
PE20191486A1 (es) 2019-10-18
CR20190429A (es) 2019-11-12
CN110431139A (zh) 2019-11-08
KR20190129923A (ko) 2019-11-20
CN110431139B (zh) 2022-07-05
AU2018234985A1 (en) 2019-10-24
SG11201908065YA (en) 2019-09-27
ECSP19066134A (es) 2019-09-30
TW201843151A (zh) 2018-12-16
CL2019002527A1 (es) 2019-11-22
CA3055258A1 (en) 2018-09-20
JP2020514344A (ja) 2020-05-21
EP3596076A1 (en) 2020-01-22
US20210347775A1 (en) 2021-11-11
PH12019502086A1 (en) 2020-03-09
EA201992090A1 (ru) 2020-03-06
US20200087300A1 (en) 2020-03-19
JOP20190209A1 (ar) 2019-09-12
DOP2019000228A (es) 2019-09-30
WO2018167203A1 (en) 2018-09-20
MX2019010898A (es) 2019-11-07
CO2019010029A2 (es) 2019-09-30

Similar Documents

Publication Publication Date Title
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
EP3393475C0 (en) CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER
MA49884A (fr) Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer
MA45550A (fr) Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
GB201519406D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL258828A (en) Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer therapy
MA46085A (fr) Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires
EP3440081A4 (en) PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
EP3937980A4 (en) Modified micrornas and their use in the treatment of cancer
EP3440083A4 (en) IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
EP3796920A4 (en) TRNA/PRE-MIRNA COMPOSITIONS AND USE IN THE TREATMENT OF CANCER
EP3380086A4 (en) USE OF CYP26 RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
GB201608227D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3576738A4 (en) USE OF GABOXADOL TO TREAT TINNITUS
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
HUE060882T2 (hu) Naftiridinon-származékok és alkalmazásuk arrhytmia kezelésében
EP3258964A4 (en) IDENTIFICATION AND TREATMENT OF MALIGNEN TUMORS IN THE CNS
EP3395341A4 (en) COMPOSITION FOR THE TREATMENT OF MOTORURON DISEASES AND USE THEREOF
GB201604182D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer